Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Variability in clinical response to standard therapeutic dosage regimen was reported in the 1950s by many pioneers in the field. Since then, the association between monogenic polymorphisms and variations of drugs’ metabolism, transport, or target had been identified and the vision of personalized drug therapy in health care envisioned [1, 2]. Pharmacogenomic-guided drug therapy for patient is based on the premise that a large portion of interindividual variability in drug response (efficacy and/or toxicity) is genetically determined. Despite the widespread recognition of the scientific rationale and the clinical implementation of pharmacogenomic tests at several major academic medical institutions [3-7], most clinicians and researchers engaged in the discipline would agree that the early vision of achieving personalized therapy in the form of therapeutic regimens tailored to an individual’s genetic profile remains some years away.

Original languageEnglish (US)
Title of host publicationOmics in Clinical Practice
Subtitle of host publicationGenomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research
PublisherApple Academic Press
Pages95-133
Number of pages39
ISBN (Electronic)9781482262438
ISBN (Print)9781771880602
DOIs
Publication statusPublished - Jan 1 2014

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Lam, Y. F. (2014). Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. In Omics in Clinical Practice: Genomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research (pp. 95-133). Apple Academic Press. https://doi.org/10.1201/b17137